Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

A major advance? EPO - MNTA Patent Application -

2016-07-12 TISSUE TARGETING

Many anti-cancer agents attack cancer cells and normal cells alike. Therapeutic approaches to selectively target cancer tissues while minimizing toxic effects against normal tissues are therefore an important pursuit.

SUMMARY OF THE INVENTION

[0003] The invention is based, at least in part, on the discovery that a low molecular weight heparin described herein (e.g., a LMWH lacking substantial anticoagulant activity, e.g., M402) conjugated to a heterologous agent exhibited selective accumulation at the site of a primary tumor when administered to an experimental animal. Accordingly, the invention features, inter alia, methods to deliver and target an agent, e.g., a therapeutic or imaging agent, to a tumor site in a subject. Also included are related methods to deliver and target an agent, e.g., a therapeutic or imaging agent, to a site of inflammation, fibrosis or infection in a subject.

Read more:
https://worldwide.espacenet.com/publicationDetails/description?CC=BR&NR=112012026542A2&KC=A2&FT=D&ND=3&date=20160712&DB=EPODOC&locale=en_EP